What’s in a NAM? Organ-on-a-Chip models from invention towards regulatory implementation

Van derden

14/04/26

Around the world, regulators are accelerating the transition toward New Approach Methodologies (NAMs), with initiatives such as the FDA Modernization Act helping drive momentum away from animal models. But while the direction is clear, full replacement in the near future is not around the corner. For NAMs to achieve regulatory-grade adoption, two challenges must be addressed: validation and reproducibility.

Join Jos Joore, PhD (CEO at MIMETAS) on Wednesday, April 14, for a live webinar exploring how organ-on-a-chip technology can move beyond innovation into regulatory-grade application and why standardized biology is the missing link.

In this webinar, you will learn:

– How the global shift toward NAMs is reshaping drug development and safety testing

– Why biological variability remains one of the biggest barriers to validation

– How MIMETAS’ OrganoReady® supports reproducibility across labs

– Real-world applications in gut toxicity and vascular inflammation

Please register here.